The Effect of Intrathecal Injection of Morphine Combined With Dexmedetomidine on the Analgesic Effect in Patients With Severe Advanced Lung Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500096912

Enrollment

Unknown

Registered

2025-02-08

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Experimental Group:Morphine combined with dexmedetomidine was injected intrathecally

Control group:Morphine was administered intrathecally

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patient was diagnosed as advanced lung cancer (TNM stage ?-?) by clinical symptoms, medical history, laboratory examination, imaging examination and puncture biopsy, accompanied by severe cancer pain. The pain was mainly characterized by persistent acid and swelling pain or occasional needle-like or electric shock pain, and NRS >6. 2. Age 20-80 years old, conscious; 3. No history of allergy to morphine or dexmedetomidine or psychosis; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Contraindications of intraspinal puncture; 2. Systemic infection or local surgical site infection; 3. Abnormal bleeding and coagulation, severe bleeding tendency; 4. Unable to cooperate with surgery due to severe illness; 5. Allergy to the implanted catheter, the pump and the drugs used in the pump; 6. Intraspinal metastasis with cerebrospinal fluid circulation disorder; 7. Severe mental illness; 8. Poor cognition or unconsciousness; 9. Patients during pregnancy and lactation; 10. Unstable angina or myocardial obstruction in the past 6 months; Previous severe angina pectoris; Congestive heart failure; 11. The investigator judged that the subjects, including but not limited to vital organ dysfunction and/or serious systemic diseases, were not suitable to participate in the clinical research; 12. When a single small dose of morphine hydrochloride injected into the subarachnoid space failed to test or had serious adverse reactions.

Design outcomes

Primary

Measure	Time frame
Numeric analogue scale ;	—

Secondary

Measure	Time frame
Dosage of morphine;Quality of sleep;Anxiety and depression;Occurrence of adverse reactions;	—

Countries

China

Contacts

Public ContactLiao Lijun

Shanghai East Hospital Affiliated to Tongji University

liao@pan-support.com+86 138 1742 8913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026